Emerging treatment combinations: integrating therapy into clinical practice.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metastatic breast cancer (MBC) treatment is evolving with a focus on targeted therapies.
• Signal-transduction pathways play a critical role in breast cancer development and progression.
• Resistance to endocrine therapy is a significant clinical challenge in MBC management.

Purpose of the Study:

• To review emerging treatment options for metastatic breast cancer.
• To evaluate the potential of novel targeted therapies and epigenetic modifiers.
• To assess the role of signal-transduction inhibitors in overcoming resistance mechanisms.

Main Methods:

• Review of recent research on signal-transduction pathways and epigenetic modifications in breast cancer.
• Analysis of data on mammalian target of rapamycin (mTOR) inhibitors, such as everolimus.
• Examination of epidermal growth factor receptor (EGFR) inhibitors in combination with endocrine therapy.
• Evaluation of histone deacetylase (HDAC) inhibitors, such as vorinostat, in combination regimens.

Main Results:

• Everolimus, an mTOR inhibitor, shows promising efficacy and a favorable safety profile in initial studies.
• EGFR inhibitors (e.g., gefitinib) may delay endocrine therapy resistance when combined with tamoxifen or aromatase inhibitors.
• Vorinostat, an HDAC inhibitor, in combination with paclitaxel and bevacizumab, achieved objective responses in over 50% of patients with recurrent/metastatic breast cancer in a Phase I/II study.

Conclusions:

• Emerging therapies targeting mTOR, EGFR, and epigenetic pathways offer new avenues for MBC treatment.
• Initial findings for everolimus, EGFR inhibitors, and vorinostat combinations are encouraging.
• Randomized controlled trials are necessary to validate the efficacy and safety of these novel approaches in MBC.